To view this email as a web page, click here.
July 4, 2019
 
The New “Sweet Spot” in Type 2 Diabetes Management
Where is the disease management “sweet spot” for this patient with diabetes, hypertension, heart failure, and sleep apnea? The answer is pleiotropic.
(©Dave/adobe.stock.com)

Read more
 
Diabetes Drugs and Cardioprotection: 8 Evidence-based Questions
Cardioprotection is a central benefit of agents in several classes of antidiabetes drugs. Which classes? Which agents? What mechanism?

Read more
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.